alanine has been researched along with Co-infection in 10 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 9.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 5.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)." | 1.46 | Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarowar, A | 1 |
| Coffin, CS | 1 |
| Fung, S | 1 |
| Wong, A | 1 |
| Doucette, K | 1 |
| Truong, D | 1 |
| Conway, B | 1 |
| Haylock-Jacobs, S | 1 |
| Ramji, A | 1 |
| Hansen, BE | 1 |
| Janssen, HLA | 1 |
| Cooper, C | 1 |
| Huhn, GD | 1 |
| Ramgopal, M | 1 |
| Jain, MK | 1 |
| Hinestrosa, F | 1 |
| Asmuth, DM | 1 |
| Slim, J | 1 |
| Goldstein, D | 1 |
| Applin, S | 1 |
| Ryu, JH | 1 |
| Jiang, S | 1 |
| Cox, S | 1 |
| Das, M | 2 |
| Nguyen-Cleary, T | 1 |
| Piontkowsky, D | 1 |
| Guyer, B | 1 |
| Rossaro, L | 1 |
| Haubrich, RH | 1 |
| Kay, AW | 1 |
| Ness, TE | 1 |
| Martinez, L | 1 |
| Mandalakas, AM | 1 |
| Spadea, M | 1 |
| Carraro, F | 1 |
| Saglio, F | 1 |
| Vassallo, E | 1 |
| Pessolano, R | 1 |
| Berger, M | 1 |
| Scolfaro, C | 1 |
| Grassitelli, S | 1 |
| Fagioli, F | 1 |
| Anton-Vazquez, V | 1 |
| Clivillé, R | 1 |
| Karris, MY | 1 |
| Tartaglia, A | 1 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 1 |
| García-Broncano, P | 1 |
| Berenguer, J | 1 |
| Fernández-Rodríguez, A | 1 |
| Pineda-Tenor, D | 1 |
| Jiménez-Sousa, MÁ | 1 |
| García-Alvarez, M | 1 |
| Miralles, P | 1 |
| Aldámiz-Echevarria, T | 1 |
| López, JC | 1 |
| Micheloud, D | 1 |
| Resino, S | 1 |
| Garcia, M | 1 |
| Le Moal, G | 1 |
| Godet, C | 1 |
| Beraud, G | 1 |
| Chagneau-Derrode, C | 1 |
| Roblot, F | 1 |
| Gallant, J | 1 |
| Brunetta, J | 1 |
| Crofoot, G | 1 |
| Benson, P | 1 |
| Mills, A | 1 |
| Brinson, C | 1 |
| Oka, S | 1 |
| Cheng, A | 1 |
| Garner, W | 1 |
| Fordyce, M | 1 |
| McCallister, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 62.5 |
| F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 69.4 |
| E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | 83.8 |
| F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) | 79.7 |
Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 95.8 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 98.6 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 1.4 |
| F/R/TAF + LDV/SOF | 1.4 |
2 trials available for alanine and Co-infection
| Article | Year |
|---|---|
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira | 2020 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em | 2016 |
8 other studies available for alanine and Co-infection
| Article | Year |
|---|---|
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Topics: Adenine; Alanine; Alanine Transaminase; Anti-Retroviral Agents; Canada; Cholesterol; Coinfection; He | 2022 |
It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.
Topics: Adenosine Monophosphate; Alanine; Antitubercular Agents; Antiviral Agents; Betacoronavirus; Coinfect | 2020 |
Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting.
Topics: Adenosine Monophosphate; Alanine; Amphotericin B; Coinfection; COVID-19; COVID-19 Drug Treatment; Dr | 2021 |
Streptococcus pneumoniae coinfection in hospitalised patients with COVID-19.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Anti-Bacterial Agents; Anti-Inflam | 2021 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study.
Topics: Adult; Alanine; Amino Acid Substitution; Cardiovascular Diseases; Coinfection; Cross-Sectional Studi | 2014 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn | 2016 |